Publicaciones en colaboración con investigadores/as de Hospital Universitario Arnau de Vilanova (31)

2021

  1. p.RQ92 mutation associated with amyloidosis

    Reumatologia Clinica, Vol. 17, Núm. 1, pp. 46-48

2016

  1. Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer

    Oncotarget, Vol. 7, Núm. 19, pp. 26979-26991

2014

  1. Role of local bioactivation of vitamin D by CYP27A1 and CYP2R1 in the control of cell growth in normal endometrium and endometrial carcinoma

    Laboratory Investigation, Vol. 94, Núm. 6, pp. 608-622

2013

  1. Gene expression microarray-based assay to determine tumor site of origin in a series of metastatic tumors to the ovary and peritoneal carcinomatosis of suspected gynecologic origin

    Human Pathology, Vol. 44, Núm. 1, pp. 20-28

2011

  1. FGFR2 alterations in endometrial carcinoma

    Modern Pathology, Vol. 24, Núm. 11, pp. 1500-1510

  2. KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels

    American Journal of Pathology, Vol. 178, Núm. 4, pp. 1529-1543

  3. Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma

    Human Pathology, Vol. 42, Núm. 2, pp. 185-193

2010

  1. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis

    Endocrine-Related Cancer, Vol. 17, Núm. 1, pp. 7-16

  2. Squamous cell carcinoma developing in Jadassohn's sebaceous nevus: Case report and review of the literature

    Dermatologic Surgery, Vol. 36, Núm. 11, pp. 1763-1768

  3. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms

    European Journal of Cancer, Vol. 46, Núm. 4, pp. 836-850

2009

  1. A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma

    Analytical and Quantitative Cytology and Histology, Vol. 31, Núm. 4, pp. 217-226

  2. CK2β is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation

    American Journal of Pathology, Vol. 174, Núm. 1, pp. 287-296

  3. Molecular pathology of endometrial carcinoma: Practical aspects from the diagnostic and therapeutic viewpoints

    Journal of Clinical Pathology, Vol. 62, Núm. 9, pp. 777-785

2008

  1. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells

    Oncogene, Vol. 27, Núm. 18, pp. 2513-2524

  2. Loss of heterozygosity in endometrial carcinoma

    International Journal of Gynecological Pathology, Vol. 27, Núm. 3, pp. 305-317

  3. Metastatic small cell carcinoma to the thyroid gland: A pathologic and molecular study demonstrating the origin in the urinary bladder

    Endocrine Pathology, Vol. 19, Núm. 3, pp. 190-196

  4. Nuclear factor-κB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma

    Human Pathology, Vol. 39, Núm. 7, pp. 994-1001

  5. Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma

    Modern Pathology, Vol. 21, Núm. 6, pp. 691-699

  6. Targeted therapies in gynecologic cancers and melanoma

    Seminars in Diagnostic Pathology, Vol. 25, Núm. 4, pp. 262-273

2007

  1. Mitral endocarditis due to Escherichia coli [4]

    Enfermedades Infecciosas y Microbiologia Clinica